Vitae Pharmaceuticals Inc. (Nasdaq: VTAE)
announced positive results from a Phase 1 clinical study of VTP-43742 in
autoimmune disorders. Shares of the biotechnology firm leaped $6.01 to $13.94.
Positive study results for Vitae Pharmaceuticals
September 09, 2015 at 14:06 PM EDT
